BNET Industries

BNET Pharma

Industry news and insights by Jim Edwards

Despite layoffs, Abbott Labs Faces Retirement Wave in 5 Years

By Jim Edwards | December 1st, 2008 @ 7:32 am

A report in Kiplinger’s notes that roughly 25 percent of the employees of Abbott Labs are age 50 or older, and in five years that number could top more than 40 percent.

The demographics are likely similar at many other large drug companies. Abbott is experimenting with a kind of “phased retirement” for some employees as they approach age 62:

  • Workers 55 or older with 10 years of service can scale back to four days a week.
  • Or they can take up to five weeks of extra vacation.
  • Or they can keep the same schedule but reduce their responsibilities — for example, dropping out of management.
  • Workers keep health, pension and 401(k) benefits as if they were still working full-time, but they can’t collect their pension.
  • They must mentor younger workers if they take part in the program.

Of course, employees must survive the layoffs that are washing over the industry in order to take advantage of all this … Abbott is only maintaining its numbers because it is going through a strict regime of laying off staff wherever it can.

Tags: Layoff, Employee, Pension, Worker, Abbott Labs, Benefits, 401(k), Workforce Management, Payroll Solutions, Retirement Plans

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools.

Email Jim Edwards or follow him on Twitter.
 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
  2.  
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement
AboutPharma Industry

BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.